Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Viking Therapeutics (NASDAQ: VKTX ) stock is taking off on Monday without any news from the biopharmaceutical company. Instead, it looks like holders of NKTX stock have Madrigal Pharmaceutica...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Piotr Swat / Shutterstock.com Aerojet Rocketdyne (NYSE: AJRD ) stock is on the move today as investors react to a $4.7 billion deal with L3Harris Technologies (NYSE: LHX ). That deal has L3Harris T...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Madrigal Pharmaceuticals (NASDAQ: MDGL ) stock is rocketing higher on Monday after sharing results from its novel therapeutics for nonalcoholic steatohepatitis (NASH) treatment. The company ...
In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses, 80 mg and 100 mg, relative to placebo NASH resolution (ballooning of 0, inflammation...
CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom o...
Summary Competitor with similar mechanism of action drug resmetirom will release results from its phase 3 MAESTRO-NASH study in Q4 of 2022. Biopsy data is going to be key for success. Viking Therapeutics will release its results from the phase 2b VOYAGE study using VK2809 for NASH in th...
Summary 4 years after releasing positive Phase 2 data for lead (and only) candidate Resmetirom in NASH we are still waiting for Phase 3 data. Madrigal's management has promised that data will arrive in Q422 - its last update came in early November. NASH is a massive market opportuni...
Summary The recent Phase 3 (MAESTRO-NAFLD-1) study delivered extremely strong results. This month, Madrigal is expected to release the data for its Phase 3 (MAESTRO-NASH) trial. Depending on the results of the said study, Madrigal shares are either going to rise to a new height or t...
Madrigal Pharmaceuticals press release ( NASDAQ: MDGL ): Q3 GAAP EPS of -$4.75 misses by $0.61 . As of September 30, 2022, Madrigal had cash, cash equivalents and marketable securities of $153.2 million, compared to $270.3 million at December 31, 2021. For furthe...
Two resmetirom oral abstracts to be presented at the AASLD Liver Meeting®: Phase 3 MAESTRO-NAFLD-1 data demonstrate the potential of resmetirom for the treatment of patients with compensated NASH cirrhosis Screening data from the Phase 3 MAESTRO-NASH biopsy study pr...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...